Literature DB >> 15994659

Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials.

Philip C Maier1, Jens Funk, Guido Schwarzer, Gerd Antes, Yngve T Falck-Ytter.   

Abstract

OBJECTIVE: Open angle glaucoma is one of the most common causes of blindness in industrialised nations. Treatments to lower ocular pressure are widely used in glaucoma prevention and treatment, despite conflicting evidence.
DESIGN: We performed meta-analyses to reassess the effectiveness of pressure lowering treatment to delay the development of glaucoma in ocular hypertension, as well as progression of manifest open angle glaucoma. DATA SOURCES: Medline, Embase, and the Cochrane Library. SELECTION OF STUDIES: Eligible studies were randomised controlled trials with a concurrent untreated control group and information on time to glaucomatous changes to visual field and optic disc. Trial reports were reviewed independently by two investigators in an unblinded standardised manner.
RESULTS: Meta-analysis of trials in ocular hypertension showed a significant preventive effect of reducing intraocular pressure on progression to glaucoma (hazard ratio 0.56, 95% confidence interval 0.39 to 0.81, P = 0.01; number needed to treat 12). Pooled data of studies in manifest glaucoma showed a significant delay of visual field deterioration (0.65, 0.49 to 0.87, P = 0.003; NNT = 7), with subgroup analysis showing a larger effect in patients with raised pressure and a reduced effect in normal tension glaucoma (subgroup comparison: not significant).
CONCLUSIONS: Lowering intraocular pressure in patients with ocular hypertension or manifest glaucoma is beneficial in reducing the risk of visual field loss in the long term.

Entities:  

Mesh:

Year:  2005        PMID: 15994659      PMCID: PMC558697          DOI: 10.1136/bmj.38506.594977.E0

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  21 in total

Review 1.  Calculating the number needed to treat for trials where the outcome is time to an event.

Authors:  D G Altman; P K Andersen
Journal:  BMJ       Date:  1999-12-04

Review 2.  Interaction revisited: the difference between two estimates.

Authors:  Douglas G Altman; J Martin Bland
Journal:  BMJ       Date:  2003-01-25

Review 3.  Measuring inconsistency in meta-analyses.

Authors:  Julian P T Higgins; Simon G Thompson; Jonathan J Deeks; Douglas G Altman
Journal:  BMJ       Date:  2003-09-06

4.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

Authors:  M K Parmar; V Torri; L Stewart
Journal:  Stat Med       Date:  1998-12-30       Impact factor: 2.373

5.  Long-term effects of timolol therapy in ocular hypertension: a double-masked, randomised trial.

Authors:  A Heijl; B Bengtsson
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2000-11       Impact factor: 3.117

6.  The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma.

Authors:  Mae O Gordon; Julia A Beiser; James D Brandt; Dale K Heuer; Eve J Higginbotham; Chris A Johnson; John L Keltner; J Philip Miller; Richard K Parrish; M Roy Wilson; Michael A Kass
Journal:  Arch Ophthalmol       Date:  2002-06

7.  The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.

Authors:  Michael A Kass; Dale K Heuer; Eve J Higginbotham; Chris A Johnson; John L Keltner; J Philip Miller; Richard K Parrish; M Roy Wilson; Mae O Gordon
Journal:  Arch Ophthalmol       Date:  2002-06

8.  Results of the betaxolol versus placebo treatment trial in ocular hypertension.

Authors:  Deborah Kamal; David Garway-Heath; Simon Ruben; Fiona O'Sullivan; Catey Bunce; Anath Viswanathan; Wendy Franks; Roger Hitchings
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-02-19       Impact factor: 3.117

9.  Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.

Authors:  Anders Heijl; M Cristina Leske; Bo Bengtsson; Leslie Hyman; Boel Bengtsson; Mohamed Hussein
Journal:  Arch Ophthalmol       Date:  2002-10

10.  Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial.

Authors:  M Cristina Leske; Anders Heijl; Mohamed Hussein; Bo Bengtsson; Leslie Hyman; Eugene Komaroff
Journal:  Arch Ophthalmol       Date:  2003-01
View more
  67 in total

1.  Low-cost rapid prototyping of liquid crystal polymer based magnetic microactuators for glaucoma drainage devices.

Authors:  Simon John
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2016-08

2.  What comparative effectiveness research is needed? A framework for using guidelines and systematic reviews to identify evidence gaps and research priorities.

Authors:  Tianjing Li; S Swaroop Vedula; Roberta Scherer; Kay Dickersin
Journal:  Ann Intern Med       Date:  2012-03-06       Impact factor: 25.391

3.  Secondary neuroprotective effects of hypotensive drugs and potential mechanisms of action.

Authors:  Grace C Shih; David J Calkins
Journal:  Expert Rev Ophthalmol       Date:  2012-04

Review 4.  Effects of travoprost in the treatment of open-angle glaucoma or ocular hypertension: A systematic review and meta-analysis.

Authors:  Jin-Wei Cheng; Gui-Lin Xi; Rui-Li Wei; Ji-Ping Cai; You Li
Journal:  Curr Ther Res Clin Exp       Date:  2009-08

5.  Preventing blindness from glaucoma.

Authors:  David B Henson; Reshma Thampy
Journal:  BMJ       Date:  2005-07-16

Review 6.  Uncertainty in heterogeneity estimates in meta-analyses.

Authors:  John P A Ioannidis; Nikolaos A Patsopoulos; Evangelos Evangelou
Journal:  BMJ       Date:  2007-11-03

7.  What's new in glaucoma treatment?

Authors: 
Journal:  Community Eye Health       Date:  2006-09

8.  In vivo optic nerve head biomechanics: performance testing of a three-dimensional tracking algorithm.

Authors:  Michaël J A Girard; Nicholas G Strouthidis; Adrien Desjardins; Jean Martial Mari; C Ross Ethier
Journal:  J R Soc Interface       Date:  2013-07-24       Impact factor: 4.118

9.  Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients.

Authors:  M Figus; M Nardi; P Piaggi; M Sartini; G Guidi; L Martini; S Lazzeri
Journal:  Eye (Lond)       Date:  2014-01-17       Impact factor: 3.775

10.  Ten-year outcomes in newly diagnosed glaucoma patients: mortality and visual function.

Authors:  Tarun Sharma; John F Salmon
Journal:  Br J Ophthalmol       Date:  2007-05-02       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.